ReviewNature reviews. Endocrinology2022
Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD.
Review in Nature reviews. Endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07189650 (Collection of Quantitative Data on Liver Fat Content Obtained From Ultrasound Attenuation), which is not on this map. Cited by 151 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Collection of Quantitative Data on Liver Fat Content Obtained From Ultrasound Attenuation (QAI) and Scattering (QSI) Imaging and From Liver Fat Fraction Values Obtained by Magnetic Resonance Imaging With Proton Density Technique (MRI-PDFF)
Who cites it
151 citing papers in PubMed, 4 syntheses or guidelines pooled it, 231 citations in OpenAlex.
- Diagnostic performance of ultrasound attenuation imaging in detecting hepatic steatosis.Journal of medical ultrasonics (2001) · 2026Pooled it
- Comparative efficacy of multiple drugs for non-alcoholic fatty liver disease: a Bayesian network meta-analysis.European journal of medical research · 2025Pooled it
- Pooled it
- Evaluation of MRI proton density fat fraction in hepatic steatosis: a systematic review and meta-analysis.European radiology · 2025Pooled it
- Multiparametric ultrasound for non-invasive assessment of liver steatosis, fibrosis, and inflammation in metabolic dysfunction-associated steatotic liver disease.World journal of gastroenterology · 2025Trial
- Screening and diagnosis of liver disease in diabetes: a guide and evidence-based assessment.Diabetologia · 2026Review
- MRI risk stratification in metabolic dysfunction-associated steatotic liver disease (MASLD): from diffuse liver disease to focal lesions.Abdominal radiology (New York) · 2026Review
- Metabolic dysfunction-associated steatotic liver disease-a review of the cardiometabolic perspectives and treatments in children.International journal of obesity (2005) · 2026Review
- From Molecular Mechanisms to Clinical Strategies: A Comprehensive Overview of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).International journal of molecular sciences · 2026Review
- Quantitative liver ultrasound: current status and challenges.Ultrasonography (Seoul, Korea) · 2026Article
- Subtype Differences in Major Adverse Liver Outcomes and Cardiovascular Events and Mortality in Steatotic Liver Disease: A UK Biobank Analysis.Alimentary pharmacology & therapeutics · 2026Article
- Article
- Fibrosis-4 index utility for screening liver fibrosis and its association with degenerative complications in patients with type 2 diabetes mellitus: a monocentric study.Medicine and pharmacy reports · 2026Article
- A Transformer-Residual Network-Integrated Deep Learning Model for Digital Pathology-Based Grading and Risk Stratification of Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Liver Fibrosis.Clinical and translational gastroenterology · 2026Article
- Coffee Consumption and Improved Liver Outcomes: Clinical, Imaging, and Proteomic Evidence From the UK Biobank.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026Article
- Quantitative ultrasound attenuation imaging outperforms B-mode scoring for assessing hepatic steatosis.Ultrasonography (Seoul, Korea) · 2026Article
- Non-invasive imaging diagnostic techniques in metabolic dysfunction-associated steatotic liver disease: a roadmap for clinicians.Hormones (Athens, Greece) · 2026Review
- Accurate and spatially stable quantification of hepatic steatosis using ultrasound-derived fat fraction in metabolic dysfunction-associated steatotic liver disease (MASLD): a prospective magnetic resonance imaging-proton density fat fraction (MRI-PDFF) study.Quantitative imaging in medicine and surgery · 2026Article
- Impact of metabolic dysfunction-associated steatotic liver disease on long-term prognosis in hepatocellular carcinoma patients undergoing hepatectomy.Hepatobiliary surgery and nutrition · 2026Article
- Steatosis index: a novel multiparametric ultrasound approach for accurate liver steatosis quantification and grading.Journal of gastroenterology · 2026Article
91 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
Abstract
Hepatic steatosis is a key histological feature of nonalcoholic fatty liver disease (NAFLD). The non-invasive quantification of liver fat is now possible due to advances in imaging modalities. Emerging data suggest that high levels of liver fat and its temporal change, as measured by quantitative non-invasive methods, might be associated with NAFLD progression. Ultrasound-based modalities have moderate diagnostic accuracy for liver fat content and are suitable for screening. However, of the non-invasive imaging modalities, MRI-derived proton density fat fraction (MRI-PDFF) has the highest diagnostic accuracy and is used for trial enrolment and to evaluate therapeutic effects in early-phase clinical trials in nonalcoholic steatohepatitis (NASH). In patients with NAFLD without advanced fibrosis, high levels of liver fat are associated with rapid disease progression. Furthermore, changes on MRI-PDFF (≥30% decline relative to baseline) are associated with NAFLD activity score improvement and fibrosis regression. However, an inverse association exists between liver fat and complications of cirrhosis. Liver fat decreases as liver fibrosis progresses towards cirrhosis, and the clinical importance of quantitative measurements of liver fat differs by NAFLD status. As such, patients with NAFLD should be stratified by fibrosis severity to investigate the utility of quantitative measurements of liver fat for assessing NAFLD progression and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.